These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 18767939)

  • 21. [Telomerase, a universal target in immunotherapy strategies against tumor?].
    Rousseau R; Soria JC
    Bull Cancer; 2000 Dec; 87(12):895-901. PubMed ID: 11174119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current developments in cancer vaccines and cellular immunotherapy.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice.
    Chen L; Tang XD; Yu ST; Ai ZH; Fang DC; Cai YG; Luo YH; Liang GP; Yang SM
    J Pathol; 2009 Apr; 217(5):685-92. PubMed ID: 19142972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current immunotherapeutic strategies in pancreatic cancer.
    Plate JM
    Surg Oncol Clin N Am; 2007 Oct; 16(4):919-43, xi. PubMed ID: 18022552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MMP11: a novel target antigen for cancer immunotherapy.
    Peruzzi D; Mori F; Conforti A; Lazzaro D; De Rinaldis E; Ciliberto G; La Monica N; Aurisicchio L
    Clin Cancer Res; 2009 Jun; 15(12):4104-13. PubMed ID: 19509157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers.
    Nava-Parada P; Emens LA
    Curr Opin Mol Ther; 2007 Oct; 9(5):490-7. PubMed ID: 17932813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Oncoimmunology: some fundamental problems of cancer immunotherapy].
    Nedospasov SA; Kuprash DV
    Mol Biol (Mosk); 2007; 41(2):355-68. PubMed ID: 17514902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telomerase-based immunotherapy of cancer.
    Carpenter EL; Vonderheide RH
    Expert Opin Biol Ther; 2006 Oct; 6(10):1031-9. PubMed ID: 16989585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telomerase in anti-tumor response.
    Batinac T; Zamolo G; Hadzisejdic I
    Med Hypotheses; 2007; 68(1):128-30. PubMed ID: 16935436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune surveillance and anti-tumor immune responses: an anatomical perspective.
    Zimmermann VS; Benigni F; Mondino A
    Immunol Lett; 2005 Apr; 98(1):1-8. PubMed ID: 15790503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunology and breast cancer: therapeutic cancer vaccines.
    Curigliano G; Rescigno M; Goldhirsch A
    Breast; 2007 Dec; 16 Suppl 2():S20-6. PubMed ID: 17706425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccines to treat cancer--an old approach whose time has arrived.
    Hellstrom KE; Hellstrom I
    J Cell Biochem; 2007 Oct; 102(2):291-300. PubMed ID: 17729239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigens for cancer immunotherapy.
    Neller MA; López JA; Schmidt CW
    Semin Immunol; 2008 Oct; 20(5):286-95. PubMed ID: 18951039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a human telomerase reverse transcriptase sequence containing two antigenic epitopes with high affinity for human leucocyte antigen.
    Wang J; Yu L; Li J; Deng R; Wang X
    Biotechnol Appl Biochem; 2007 Oct; 48(Pt 2):93-9. PubMed ID: 17868023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.